Prognostic value of 18F‐fluoroazomycin arabinoside PET/CT in patients with advanced non‐small‐cell lung cancer |
| |
| Authors: | Tsuneo Saga Masayuki Inubushi Mitsuru Koizumi Kyosan Yoshikawa Ming‐Rong Zhang Katsuyuki Tanimoto Atsushi Horiike Noriko Yanagitani Fumiyoshi Ohyanagi Makoto Nishio |
| |
| Affiliation: | 1. Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan;2. Department of Nuclear Medicine, Kawasaki Medical School, Kurashiki, Japan;3. Department of Nuclear Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan;4. Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan;5. Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan |
| |
| Abstract: | This study evaluated the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18F‐fluoroazomycin arabinoside (FAZA) in patients with advanced non‐small‐cell lung cancer (NSCLC) compared with 18F‐fluorodeoxyglucose (FDG). Thirty‐eight patients with advanced NSCLC (stage III, 23 patients; stage IV, 15 patients) underwent FAZA and FDG PET/CT before treatment. The PET parameters (tumor‐to‐muscle ratio T/M] at 1 and 2 h for FAZA, maximum standardized uptake value for FDG) in the primary lesion and lymph node (LN) metastasis and clinical parameters were compared concerning their effects on progression‐free survival (PFS) and overall survival (OS). In our univariate analysis of all patients, clinical stage and FAZA T/M in LNs at 1 and 2 h were predictive of PFS (P = 0.021, 0.028, and 0.002, respectively). Multivariate analysis also indicated that clinical stage and FAZA T/M in LNs at 1 and 2 h were independent predictors of PFS. Subgroup analysis of chemoradiotherapy‐treated stage III patients revealed that only FAZA T/M in LNs at 2 h was predictive of PFS (P = 0.025). The FDG PET/CT parameters were not predictive of PFS. No parameter was a significant predictor of OS. In patients with advanced NSCLC, FAZA uptake in LNs, but not in primary lesions, was predictive of treatment outcome. These results suggest the importance of characterization of LN metastases in advanced NSCLC patients. |
| |
| Keywords: | 18F‐fluoroazomycin arabinoside (FAZA) 18F‐fluorodeoxyglucose (FDG) non‐small‐cell lung cancer positron emission tomography/computed tomography (PET/CT) prognosis |
|
|
